Royalty Pharma plc beat EPS estimates 94% of the time across 16 reported quarters (15 beats, 1 misses), averaging +5.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.27 | $1.32 | +3.9% | Beat | Q2 FY26 call |
| Q1 FY26 | $1.22 | $1.30 | +6.6% | Beat | |
| Q4 FY25 | $1.33 | $1.46 | +9.8% | Beat | Q4 FY25 call |
| Q3 FY25 | $1.11 | $1.17 | +5.4% | Beat | |
| Q2 FY25 | $1.10 | $1.14 | +3.6% | Beat | |
| Q1 FY25 | $0.99 | $1.06 | +7.1% | Beat | |
| Q4 FY24 | $1.09 | $1.15 | +5.5% | Beat | |
| Q3 FY24 | $0.95 | $1.04 | +9.5% | Beat | |
| Q2 FY24 | $0.95 | $0.96 | +1.1% | Beat | |
| Q1 FY24 | $0.96 | $0.98 | +2.1% | Beat | |
| Q4 FY23 | $1.03 | $1.15 | +11.7% | Beat | |
| Q3 FY23 | $0.81 | $0.79 | -2.5% | Miss |
Back to RPRX overview · RPRX holders · RPRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.